Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03116087 · ClinicalTrials.gov registry record · NA
Testosterone Replacement in Postmenopausal Women With Stress Urinary Incontinence
A NA study, sponsored by Charles Drew University of Medicine and Science.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT03116087 is a NA study that has completed, run by Charles Drew University of Medicine and Science. The registered enrollment target is 60 participants.
The verdict
NCT03116087, a NA study, has completed, sponsored by Charles Drew University of Medicine and Science.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
The overall objective of this study is to establish if testosterone replacement in post-menopausal women with low testosterone levels and stress urinary incontinence (SUI) will lead to improvement in symptoms of SUI. This study is a prospective, randomized, double-blind, placebo-controlled, parallel-group, clinical trial and will involve sixty (60) post-menopausal women with clinically diagnosed stress urinary incontinence and low testosterone concentrations. These subjects will enter the control period, which involves the baseline measurements of pelvic floor muscle volume and strength, amounts of urine leakage in 24-hour period, urodynamic parameters, and quality of life using Incontinence Impact Questionnaire and Urogenital Distress Inventory. Subjects are then randomly assigned to either placebo (30 subjects) or 300 mcg/twice-weekly testosterone patch (30 subjects) group. Both the subjects and investigators will be blinded. The duration of the testosterone/control study will be 36 weeks, with weeks 1-3 screening/control period, 4-28 application of placebo or testosterone patches and 29-36 recovery time/assessment of effects.
Interventions
- DRUG Placebo
- DRUG Testosterone patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-03-01 |
| Est. Completion | 2018-05-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03116087
The ClinicalTrials.gov registry entry for NCT03116087 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charles Drew University of Medicine and Science, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03116087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03116087 about?
NCT03116087 is a clinical study titled "Testosterone Replacement in Postmenopausal Women With Stress Urinary Incontinence". The overall objective of this study is to establish if testosterone replacement in post-menopausal women with low testosterone levels and stress urinary incontinence (SUI) will lead to improvement in symptoms of SUI. This study is a prospective, randomized, double-blind, placebo-controlled, paralle...
What is the current status of trial NCT03116087?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2007-03-01. Estimated completion is 2018-05-31.
What interventions are being tested in trial NCT03116087?
The interventions under investigation include: Placebo (DRUG), Testosterone patch (DRUG).
Who is sponsoring clinical trial NCT03116087?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.